TNFRSF8 and Hodgkins lymphoma: This led to initiation of clinical studies in the 1990s to improve post-ASCT outcomes and consequently improve HL cure rates [14, 15], many of which showed less than satisfactory results, until the introduction of post-ASCT consolidation with brentuximab vedotin, an anti-cluster of differentiation 30 (CD30) antibody-drug conjugate (ADC).